JP2024521073A - 大環式(macrocyclic)グルカゴン様ペプチド1受容体アゴニスト - Google Patents

大環式(macrocyclic)グルカゴン様ペプチド1受容体アゴニスト Download PDF

Info

Publication number
JP2024521073A
JP2024521073A JP2023571304A JP2023571304A JP2024521073A JP 2024521073 A JP2024521073 A JP 2024521073A JP 2023571304 A JP2023571304 A JP 2023571304A JP 2023571304 A JP2023571304 A JP 2023571304A JP 2024521073 A JP2024521073 A JP 2024521073A
Authority
JP
Japan
Prior art keywords
mmol
preparation
methyl
title compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571304A
Other languages
English (en)
Japanese (ja)
Inventor
チチャロ,フランシスコ ハビエル アゲジャス
アレジャンドロ バウアー,レナト
グレゴリー ベル,マイケル
チェン,チ
ロバート カミング,グラハム
フィールズ,トッド
リン ゲルナート,ダグラス
ダニエル ホ,ジョセフ
アベルカダー カオウディ,タルビ
ジャン マスキュリン,ティエリー
オルテガ,ホセ ミゲル ミンゲツ
ソーラー,ジュリアン プリエゴ
ハーゲタ アントニオ ロドリゲス
マイケル ウォーリー,エリック
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024521073A publication Critical patent/JP2024521073A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023571304A 2021-05-20 2022-05-19 大環式(macrocyclic)グルカゴン様ペプチド1受容体アゴニスト Pending JP2024521073A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191034P 2021-05-20 2021-05-20
US63/191,034 2021-05-20
US202163254564P 2021-10-12 2021-10-12
US63/254,564 2021-10-12
EP21383172.0 2021-12-21
EP21383172 2021-12-21
PCT/US2022/029958 WO2022246019A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du récepteur du peptide 1 de type glucagon

Publications (1)

Publication Number Publication Date
JP2024521073A true JP2024521073A (ja) 2024-05-28

Family

ID=82016585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571304A Pending JP2024521073A (ja) 2021-05-20 2022-05-19 大環式(macrocyclic)グルカゴン様ペプチド1受容体アゴニスト

Country Status (8)

Country Link
EP (1) EP4341255A1 (fr)
JP (1) JP2024521073A (fr)
KR (1) KR20230173166A (fr)
AU (1) AU2022275931A1 (fr)
BR (1) BR112023022851A2 (fr)
CA (1) CA3218345A1 (fr)
IL (1) IL308397A (fr)
WO (1) WO2022246019A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102625A1 (fr) * 2022-11-11 2024-05-16 Eli Lilly And Company Agonistes de récepteur du peptide 1 de type glucagon

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060533T2 (hu) 2016-12-16 2023-03-28 Pfizer GLP-1 receptor agonisták és alkalmazásuk
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Glp-1受體促效劑及其用途
PT3806855T (pt) 2018-06-15 2023-05-03 Pfizer Agonistas dos receptores de glp-1 e suas utilizações
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
CU20210083A7 (es) 2019-04-12 2022-05-11 Qilu Regor Therapeutics Inc Agonistas de glp-1r
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (fr) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
JP2022552735A (ja) 2019-10-25 2022-12-19 ギリアード サイエンシーズ, インコーポレイテッド Glp-1r調節化合物
WO2021096284A1 (fr) 2019-11-15 2021-05-20 일동제약(주) Agoniste du récepteur glp-1 et son utilisation
EP4069686A4 (fr) 2019-12-02 2022-11-09 Hyundai Pharm Co., Ltd. Agoniste du récepteur glp-1
CN115335374A (zh) 2020-01-29 2022-11-11 吉利德科学公司 Glp-1r调节化合物
JP2023515404A (ja) 2020-02-13 2023-04-13 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
AU2021237185B2 (en) 2020-03-18 2023-11-30 Lg Chem, Ltd. GLP-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4143183A4 (fr) 2020-04-29 2024-05-15 Gasherbrum Bio, Inc. Agonistes hétérocycliques du glp -1
EP4155313A4 (fr) 2020-06-04 2023-09-13 Hangzhou Sciwind Biosciences Co., Ltd. Composé imidazole hétéroaromatique à cinq chaînons et son utilisation
CN115697338A (zh) 2020-06-10 2023-02-03 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115916772A (zh) 2020-06-19 2023-04-04 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2021259309A1 (fr) 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Agoniste du récepteur glp-1, composition pharmaceutique et utilisation associées
TW202214622A (zh) 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Glp-1r促效劑及其用途
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
PE20231206A1 (es) 2020-08-21 2023-08-17 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
WO2022042691A1 (fr) 2020-08-28 2022-03-03 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
AU2021306414A1 (en) 2020-09-01 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
WO2022068772A1 (fr) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
CN116547278A (zh) 2020-10-13 2023-08-04 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022078407A1 (fr) 2020-10-13 2022-04-21 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Also Published As

Publication number Publication date
EP4341255A1 (fr) 2024-03-27
TW202310838A (zh) 2023-03-16
IL308397A (en) 2024-01-01
BR112023022851A2 (pt) 2024-01-23
WO2022246019A1 (fr) 2022-11-24
CA3218345A1 (fr) 2022-11-24
KR20230173166A (ko) 2023-12-26
AU2022275931A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7256300B2 (ja) グルカゴン様ペプチド1受容体アゴニスト
AU2018212593B2 (en) Tyrosine amide derivatives as Rho- kinase inhibitors
JP2023515404A (ja) ヘテロ環glp-1アゴニスト
TW201249845A (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP2023513272A (ja) ヘテロ環glp-1アゴニスト
US11858918B2 (en) GLP-1R modulating compounds
JP2022502495A (ja) チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
AU2022260487A1 (en) Carboxy-benzimidazole glp-1r modulating compounds
JP2017536399A (ja) 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用
EP3807273B1 (fr) Dérivés d'azaindole comme inhibiteurs de la kinase rho
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
WO2013051672A1 (fr) Agent médicinal comprenant un dérivé de thiazolidine ou sel de celui-ci comme ingrédient actif
JP2024521073A (ja) 大環式(macrocyclic)グルカゴン様ペプチド1受容体アゴニスト
JP2016124810A (ja) 新規縮合ピラゾール誘導体およびその医薬用途
TWI843104B (zh) 類升糖素肽1受體促效劑
CN117355517A (zh) 大环胰高血糖素样肽1受体激动剂
TWI843949B (zh) 黑皮質素4(melanocortin 4)受體拮抗劑及其用途
WO2024102625A1 (fr) Agonistes de récepteur du peptide 1 de type glucagon
WO2024107781A1 (fr) Agonistes du récepteur du glucagon-like peptide 1
WO2024020350A1 (fr) Inhibiteurs de tead et procédés d'utilisation
TW202413347A (zh) Glp-1r調節化合物
CA3202134A1 (fr) Derives de dihydrofuropyridine utilises comme inhibiteurs de la rho kinase
TW201433567A (zh) 吲唑衍生物
KR20110109917A (ko) 신규한 퀴녹살린 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240126